The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …

Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …

Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors
(TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types. While …

Human carcinomas frequently express one or more members of the epidermal growth factor
receptor family. Two family members, epidermal growth factor receptor (EGFR) and c …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

Recent technological advances, together with the discovery of the important role many
growth factors play in modulating cell proliferation and differentiation, have led to the …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Cetuximab (Erbitux, IMC‐C225) is a monoclonal antibody targeted to the epidermal growth
factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined …